share_log

Azenta, Inc. (NASDAQ:AZTA) Sees Significant Decrease in Short Interest

Defense World ·  Jan 23, 2023 01:01

Azenta, Inc. (NASDAQ:AZTA – Get Rating) was the target of a significant decline in short interest in December. As of December 30th, there was short interest totalling 7,480,000 shares, a decline of 5.1% from the December 15th total of 7,880,000 shares. Approximately 11.1% of the shares of the company are sold short. Based on an average daily volume of 874,400 shares, the short-interest ratio is presently 8.6 days.

Azenta Stock Performance

Azenta stock opened at $55.75 on Monday. Azenta has a one year low of $37.61 and a one year high of $93.39. The business has a fifty day moving average of $58.83 and a two-hundred day moving average of $55.55. The company has a market cap of $3.85 billion, a P/E ratio of 1.97 and a beta of 1.61.

Get Azenta alerts:

Azenta (NASDAQ:AZTA – Get Rating) last released its earnings results on Monday, November 14th. The company reported $0.16 EPS for the quarter, beating analysts' consensus estimates of $0.06 by $0.10. Azenta had a return on equity of 1.31% and a net margin of 383.23%. The company had revenue of $137.57 million during the quarter, compared to the consensus estimate of $132.01 million. Sell-side analysts predict that Azenta will post 0.33 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Kayne Anderson Rudnick Investment Management LLC purchased a new stake in Azenta in the 2nd quarter valued at about $300,687,000. William Blair Investment Management LLC acquired a new position in Azenta during the 2nd quarter worth approximately $232,008,000. Artisan Partners Limited Partnership acquired a new position in Azenta during the 2nd quarter worth approximately $221,422,000. Macquarie Group Ltd. acquired a new position in Azenta during the 2nd quarter worth approximately $160,068,000. Finally, State Street Corp acquired a new position in Azenta during the 2nd quarter worth approximately $141,290,000. Institutional investors and hedge funds own 96.42% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Needham & Company LLC boosted their price target on Azenta from $74.00 to $78.00 and gave the company a "buy" rating in a research report on Tuesday, November 15th. KeyCorp dropped their price target on Azenta from $90.00 to $70.00 and set an "overweight" rating on the stock in a research report on Monday, October 24th. Stephens boosted their price target on Azenta from $60.00 to $65.00 in a research report on Thursday, November 17th. Finally, TheStreet upgraded Azenta from a "d+" rating to a "c-" rating in a research report on Tuesday, December 13th. Four analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $72.60.

Azenta Company Profile

(Get Rating)

Azenta, Inc is a provider of life sciences sample exploration and management solutions for the life sciences market. It operates through the Life Sciences Products and Life Sciences Services segments. The Life Sciences Products segment is involved in automated cold storage solutions for biological and chemical compound samples.

Featured Articles

  • Get a free copy of the StockNews.com research report on Azenta (AZTA)
  • Chevron is Likely to Increase its Dividend Before Earnings
  • MarketBeat Week in Review – 1/16 – 1/20
  • Does Old Dominion Show That Trucking Is Hitting The Brakes?
  • Nordstrom Puts Fear Of Markdowns Into Retail Sector
  • Exxon Mobil Stock: Within Striking Distance Of Buy Point

Receive News & Ratings for Azenta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Azenta and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment